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Many efforts have been made to better characterize specific subgroups of patients with AML by defining biological markers associated with aggressive disease. Scott et al.
2 have identified a subset of adult patients with myeloid/natural killer (NK) acute leukemia misdiagnosed as M3v. Other reports have shown a strong correlation between CD56 expression and a poor clinical prognosis in adults with AML. 3 In addition, even if little is known about the molecular mechanisms that regulate blast migration to tissues, adhesion receptors are likely to play an important role in this process. 4 We have attempted to identify the molecular characteristics of an aggressive subset of pediatric patients with AML through a prospective evaluation of CD56 þ neural cell adhesion molecule (NCAM) and CD94 expression. We analyzed a total population of 44 children with AML, distributed as follows: five with M3v (group A), nine with acute promyelocytic leukemic (APL) (group B) and 30 with non-APL AML (group C). Characteristics of patients in group A, B and C are listed in Table 1 . All cases were diagnosed and treated in our institution from January 1997 to June 2006, using ongoing protocols (see Table 1 ). Peripheral blood and bone marrow leukemia specimens were collected at the time of AML diagnosis and evaluated according to the French-AmericanBritish criteria. 5 The patient (AC) from group A was morphologically diagnosed as having an M3v (Figures 1a and b) . She was, however, found to have an NK cell leukemia, as shown by lack of expression of HLA-DR, CD2 and CD9 antigens and by the coexpression of various myeloid (CD33 and CD13) and NK cellassociated (CD56) surface antigens. To confirm our diagnosis of NK leukemia, we performed a reverse transcription-PCR (RT-PCR) assay to detect NCAM and CD94 transcripts, as described in Supplementary text. CD56 þ NK lymphoma cells were used as positive control. We found a strong expression of both NCAM and CD94 genes (Figure 1c : Lanes 1 and 2). Because the child died of complications during the early days of induction, we decided to screen our AML population to find a correlation between the expression of NK-related genes and ED (before day 15: dead of complications). To evaluate cytoplasmatic expression of NCAM and CD94 counterparts, we developed an RT-PCR semiquantitative methodology, using specific primers from NCAM, CD94 and b-actin as internal quality and quantity control. The sequences of the primers related to CD94 are listed in Supplementary text. We amplified a serial dilution of cDNA derived from case AC ranging from 100 ng to 0.01 ng, assigning a score reflecting high (Figure 1d ). We used only specimens containing more than 95% of blasts to exclude contamination from normal NK cells. We found that 9 out of 14 cases, presenting with a high level of NCAM/CD94 expression, died of disease-related events during the early days of induction. They mainly died of hemorrhagic complication (six cases) as well as disseminated intravascular coagulation (three cases). Potential risk factors for death in induction were identified by univariate analysis. The following characteristics of patients were examined as risk features: hepatomegaly, splenomegaly, WBC count (cut off 50 000 ml À1 ), platelet count (cut off 30 000 ml À1 ), CD56 expression and NCAM/CD94 genes expression. Univariate analysis showed that death in induction was significantly associated with CD56 expression only in group B (Po0.05). However, in group A, we found that all patients died during induction showing high expression of NCAM/CD94 genes. In group B and C, we found a significant association between negative or low level of NCAM/ CD94 expression and no ED (Po0.05). Considering the entire population of patients, negative or low level of NCAM/CD94 genes expression was found to have a protective role for occurrence of ED in induction (Po0.000; RR: 0.357-CI 95%: 0.177-0.721). More details are shown in Supplementary Table. In an attempt to better characterize the phenomenon of blast lyses after chemotherapy exposure, we performed an in vitro MTT cytotoxic assay using cells from case AC. 6 The effects of both cytosine arabinoside and daunorubicin at different concentrations ranging from 0.5 to 2 mg ml À1 . Although not dose dependent, this analysis showed a rapid and dramatic (more than 80%) decrease in cell viability, presumably representing an in vitro counterpart of the in vivo blast lysis phenomenon ( Figure 1e ). Our findings indicate that there is NCAM/CD94 cytoplasmatic expression in CD56 À leukemic cells. This presumably support the Scott et al.
2 hypothesis of a common precursor. It also supports the adverse prognosis significance of NK-related gene expression in some cases, as observed in adults using cytofluorimetric methodology.
3 Our work suggests that the pathogenesis of ED during induction in children with AML is explained by the phenomenon involving NK-related gene products. This probably play a role in initiating such fatal complication events as cerebral hemorrhages or disseminated intravascular coagulation. Recently, it has been shown that there is a clear correlation between CD56 positivity and ED.
7 This is mediated through leukostasis in AML that involves the monocytic lineage.
7 Although recent data showed a different pattern between M3 and M3v subtypes, 8 we here found that patients with APL are more involved than others. Never- Table 1 Characteristics of children with FAB M3v (group A), acute promyelocytic leukemia (APL) (group B) and non-APL AML (group C): clinical, morphologic, immunophenotypic and molecular findings Letters to the Editor theless, a high expression of NK-related genes is associated with the occurrence of ED and life-threatening events during induction regardless of French-American-British subtypes, representing an independent risk factor. Our data strongly suggest that doses and timing of chemotherapy induction in children with AML need to be modulated because of the high risk of hemorrhagic events. These factors appear to be related to the presence of high concentration of adhesion molecules secondary to acute blast lysis and to the associated severe coagulopathy. We do not know any pharmacological correctives for this phenomenon. It would be important to develop specifically designed molecules to disrupt the interactions with adhesion molecules, and thus to improve the clinical course of both children and adults with AML during the early days of induction. In conclusion, additional prospective studies are required to further confirm these findings in a larger group of patients with AML. In vitro citotoxicity assay for case AC: effect of both cytosine arabinoside (Ara-C) and daunorubicin (DNR) was tested at different concentrations ranging from 0.5 to 2 mg ml À1 , using the MTT assay. 8 We also tested the citotoxic effect of methotrexate reaching comparable result as well as the other chemotherapic drugs. The analysis of citotoxic effect showed a rapid (3 days) and dramatic (480%) decrease in cell viability.
with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336. The risk of secondary myelodysplastic syndromes/acute myeloid leukemia (tMDS/AML) after lymphoma treatment is still a matter of discussion, but a recent review concluded that it may reach 10% within 10 years of primary therapy. 1 Fludarabine-containing regimens have been reported to increase the risk of secondary myeloid neoplasia, particularly when combined with alkylating agents.
2 From our series of 156 lymphoma patients, we identified 19 consecutive patients who had received combination chemotherapy containing fludarabine (25 mg m À2 for days 1-3), plus novantrone (10 mg m À2 for day 1) and dexamethasone (20 mg for days 1-5 every 4 weeks) (FND) or fludarabine (25 mg m À2 for days 1-3) and cyclophosphamide (250 mg m À2 for days 1-3), with or without rituximab (r). Clinical characteristics of the selected cohort are reported in Table 1 .
The mean and median follow-up for the entire group was 53 and 50 months, respectively. Two patients who were lost to follow-up were censored at the time of the last visit. The two cases complicated by secondary myeloid disorder were observed and briefly described.
Case report Case 1. The patient, a 75-year-old man, was diagnosed as having follicular lymphoma grade II, Stage IVA, in July 2001. After informed consent, he entered in a protocol under which he received four cycles of FND-r. He attained complete (molecular) remission and was regularly followed up to June 2005, when he became febrile and was found pancytopenic. Bone marrow biopsy and cytologic examination showed hypoplasia with 20% myeloid blast cells and dysplastic erythroid features. Cytogenetic analysis showed normal karyotype in 10% of metaphases and 90% metaphases with 5,9 and 17 monosomy, extra material on short arm of chromosome 10 and 13, deletion of long arm of chromosome 20 and two markers (46, XY/45, XY; À5, À9, À17, 13p þ , 10p þ , del20q11, þ mar, þ mar). He received lowintensity antileukemic therapy and died 2 months later. 
